Nanocarriers for Drug-Targeting Brain Tumors
View on ScienceDirect

Nanocarriers for Drug-Targeting Brain Tumors

1st Edition - June 21, 2022

Write a review

  • Editors: Lalit Kumar, Yashwant Pathak
  • Paperback ISBN: 9780323907736
  • eBook ISBN: 9780323914710

Purchase options

Purchase options
Available
DRM-free (PDF, EPub)
eBook Format Help
Sales tax will be calculated at check-out

Institutional Subscription

Support CenterReturns & Refunds
Free Global Shipping
No minimum order

Description

Nanocarriers for Drug-Targeting Brain Tumors covers different types of nanocarriers and  their design and development for targeting drugs to the brain. The book also presents case studies and the mechanism of action of nanocarriers in drug targeting to a specific site. This helps researchers and clinicians understand the design, development and mechanism of action of nanocarriers. As brain tumors continue to be a significant health problem globally, and very complex for targeting drugs, conventional dosage forms are not very effective and side-effects are a major concern. Functionalized nanocarriers can address these problems. Furthermore, the targeting of nanocarriers is preferred for reducing toxicity and improving the effectiveness of the drugs. However, there is a need for understanding the design and development of formulation with the mechanism of action of nanocarriers for brain targeting.

Key Features

  • Provides information on the design and development of nanocarriers for targeting brain tumors
  • Outlines the working principles of different nanocarriers for targeting brain tumors
  • Includes case studies of different nanocarriers for targeting brain tumors

Readership

Materials scientists and engineers

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Dedication
  • Contributors
  • Preface
  • Part A: Anatomy and physiology of the brain
  • 1: An overview of the anatomy and physiology of the brain
  • Abstract
  • 1: Nervous system
  • 2: Human nervous system
  • 3: Embryonic development of the CNS (brain)
  • 4: Central nervous system (CNS)
  • 5: Cranial nerves
  • 6: Neuronal circuits
  • References
  • 2: Blood-brain barrier and central nervous system drug delivery: Challenges and opportunities
  • Abstract
  • 1: Introduction
  • 2: Pathways and challenges for drug delivery to the CNS
  • 3: Strategies and opportunities for drug delivery to CNS
  • 4: Conclusion
  • References
  • Part B: Pharmacological and clinical problems
  • 3: Challenges in targeting to brain and brain tumors
  • Abstract
  • 1: Introduction
  • 2: Barriers to brain targeting
  • 3: Transport mechanism across the blood-brain barrier
  • 4: Modern concepts for brain-targeted drug delivery
  • 5: Nose-to-brain targeted delivery system
  • 6: Factors affecting the design of the drug targeting system
  • 7: Conclusion and future prospects
  • References
  • 4: Potential targeting sites in brain and brain tumors
  • Abstract
  • 1: Introduction
  • 2: Introduction regarding the targeting sites in the brain
  • 3: Therapeutic targets of brain tumors
  • 4: Drug targeting through tumor microenvironment
  • 5: Conclusion
  • References
  • 5: Drug resistance problems in chemotherapy
  • Abstract
  • 1: Introduction
  • 2: Pharmacokinetic factors that cause drug resistance in chemotherapy
  • 3: Pharmacodynamic factors that cause drug resistance in chemotherapy
  • 4: Pharmacogenomic factors that cause drug resistance in chemotherapy
  • 5: Future directions
  • 6: Conclusion
  • References
  • Part C: Introduction and biomedical applications of nanocarriers
  • 6: An overview on nanocarriers
  • Abstract
  • 1: Introduction
  • 2: Nanocarriers
  • 3: Role of physicochemical properties in nanotoxicities
  • 4: Classification
  • 5: Applications of nanocarriers in drug delivery
  • 6: Types of polymer used in the preparation of nanocarriers
  • 7: Preparation techniques
  • 8: Characterization and evaluation
  • 9: Nanocarriers targeting the brain
  • 10: Nanotechnology-based natural compounds delivery
  • 11: Conclusion and future scope
  • References
  • 7: Biomedical applications of nanocarriers in brain tumor targeting
  • Abstract
  • 1: Introduction
  • 2: Liposomes
  • 3: Exosomes
  • 4: Niosomes
  • 5: Nanoemulsions
  • 6: Lipid nanocapsules
  • 7: Solid lipid nanoparticles (SLNs)
  • 8: Nanostructured lipid carriers (NLCs)
  • 9: Polymeric nanocarriers for brain tumor targeting
  • 10: Polymeric micelle-based nanocarriers for brain tumor targeting
  • 11: Dendrimers in brain tumor targeting
  • 12: Metallic nanoparticles for brain tumor targeting
  • 13: Future outlook of nanocarriers regarding brain tumor targeting
  • 14: Conclusion
  • References
  • Part D: Lipophilic nanocarriers
  • 8: Solid lipid nanoparticles based drug delivery for targeting brain tumors
  • Abstract
  • Acknowledgments
  • Conflict of interest
  • 1: Introduction
  • 2: SLNs: Principles and characterizations
  • 3: Applications of SLN in treating brain tumors
  • 4: Conclusion
  • References
  • 9: Nanostructured lipid carriers as an alternative carrier with high drug loading for targeting to brain tumors
  • Abstract
  • Acknowledgment
  • Conflict of interest
  • 1: Introduction
  • 2: Nanoformulations for targeted drug delivery
  • 3: Nanostructured lipid carriers (NLCs)
  • 4: Development of NLCs
  • 5: Types of NLCs
  • 6: Preparation of NLCs
  • 7: Drug encapsulation in NLCs
  • 8: Advantages and disadvantages of NLCs
  • 9: Drug loading capacity of NLCs
  • 10: Design of experimental approach for the preparation of NLCs
  • 11: Delivery of drugs to the brain
  • 12: Brain tumor therapy and challenges
  • 13: Surface modifiers for targeted drug delivery systems
  • 14: NLCs for the treatment of glioblastoma multiforme
  • 15: NLCs for encapsulation of natural anticancer agents
  • 16: Nose to brain delivery of drugs
  • 17: Conclusion
  • References
  • 10: Liposomes in drug targeting to brain tumors
  • Abstract
  • Conflict of interest
  • 1: Introduction
  • 2: Brain tumors
  • 3: Drug delivery to the brain: BBB and BBTB as critical barriers
  • 4: Liposomes for targeting brain tumors
  • 5: Transport mechanisms of liposomes in targeting brain tumors
  • 6: Functionalized liposomes for circumventing the BBB
  • 7: Multifunctional liposomes for theragnostic applications in brain tumors
  • 8: Unsolved challenges and current clinical status of liposomes in brain tumor targeting
  • 9: Conclusion
  • References
  • 11: Niosomes based drug delivery in targeting brain tumors
  • Abstract
  • 1: Introduction
  • 2: Niosomes components
  • 3: Advantages and disadvantages of niosomal carriers
  • 4: Niosomes modifications
  • 5: Niosomal-based drug delivery system
  • 6: The mechanism for crossing the BBB and drug delivery
  • 7: Conclusions and future perspectives
  • References
  • 12: Nanoemulsions as effective carriers for targeting brain tumors
  • Abstract
  • Acknowledgment
  • 1: Introduction
  • 2: Nanotechnology in brain targeting
  • 3: Nanoemulsion
  • 4: Nanoemulsions for drug targeting to brain tumors
  • 5: Nanoemulsions in current pharmacotherapeutic protocols for cancer
  • 6: Nanoemulsion-based targeted and nontargeted delivery to brain tumors
  • 7: Routes of administration
  • 8: Future prognosis and regulatory aspects
  • 9: Conclusion and future trends
  • References
  • Part E: Polymeric nanocarriers
  • 13: Mechanism of polymeric micelles for drug targeting to brain tumors
  • Abstract
  • Acknowledgments
  • Conflict of interest
  • 1: Introduction
  • 2: Structure of polymeric micelles
  • 3: Composition
  • 4: Mechanisms for targeting PMs to brain tumors
  • 5: Passive targeting (EPR effect)
  • 6: Active targeting
  • 7: Ligand-coupled micelles
  • 8: Conclusion
  • References
  • 14: Dendrimers as carriers for active targeting of brain tumors
  • Abstract
  • 1: Introduction
  • 2: Clinical manifestations and diagnosis of brain tumors
  • 3: Pathophysiology of brain tumors
  • 4: Challenges in targeting brain tumors
  • 5: Role of nanoparticles in brain targeting
  • 6: Dendrimers
  • 7: Structure and chemistry
  • 8: Types of dendrimers
  • 9: Synthesis of dendrimers
  • 10: Methods for encapsulating drugs into dendrimers
  • 11: Applications
  • 12: Dendrimers as carriers for active targeting of brain tumors
  • 13: Conclusion
  • References
  • 15: Multifunctional polymeric nanocarriers for targeting brain tumors
  • Abstract
  • Author contributions
  • Conflict of interest
  • Funding
  • 1: Introduction
  • 2: Applications of multifunctional polymers in treatment therapies of brain tumors
  • 3: Conclusion
  • References
  • 16: Polymersomes for targeting to brain tumors
  • Abstract
  • 1: Introduction
  • 2: Structure and properties of polymersomes
  • 3: Preparation of polymersomes
  • 4: Characterizations of polymersomes
  • 5: Types of polymersomes
  • 6: Polymersomes for targeting brain tumors
  • 7: Future perspectives
  • References
  • Part F: Metallic nanocarriers systems
  • 17: Development and applications of gold nanoparticles for targeting brain tumors
  • Abstract
  • Acknowledgment
  • Conflict of interest
  • 1: Introduction to brain tumors
  • 2: Gold nanoparticles for brain tumors
  • 3: Applications of GNPs for brain tumors
  • 4: Conclusion
  • References
  • 18: Gold nanoparticles in cancer theranostics
  • Abstract
  • Acknowledgment
  • 1: Introduction
  • 2: Types of AuNPs
  • 3: Cancer imaging using AuNPs
  • 4: AuNPs in cancer therapy
  • 5: Conclusions
  • References
  • 19: Silver nanoparticles in brain tumor targeting
  • Abstract
  • 1: Introduction
  • 2: Nanoparticles as targeted drug delivery systems for treating brain tumors
  • 3: Silver nanoparticles as drug delivery systems
  • 4: Applications of silver nanoparticles in targeting brain tumors
  • 5: Fate of silver nanoparticles
  • 6: Toxicity aspects of silver nanoparticles
  • 7: Conclusion
  • References
  • Part G: Hybrid nanocarriers
  • 20: Hybrid nanoparticles to cross the blood–brain barrier
  • Abstract
  • 1: Introduction
  • 2: Blood–brain barrier: Salient features
  • 3: Drug transport and the blood–brain barrier
  • 4: Uptake mechanisms of nanoparticles across the blood–brain barrier
  • 5: Hybrid nanoparticles for brain drug delivery
  • 6: Conclusion
  • References
  • 21: Targeting of lipid/polymeric (hybrid) nanoparticles to brain tumors
  • Abstract
  • 1: Introduction
  • 2: Lipid-polymer hybrid nanoparticles
  • 3: Synthesis of lipid-polymer hybrid nanoparticles
  • 4: Characterization of lipid-polymer hybrid nanoparticles
  • 5: Conclusion
  • References
  • 22: Nano-enabled systems for neural tissue regenerative applications
  • Abstract
  • Acknowledgments
  • Conflict of interest
  • 1: Introduction
  • 2: Nano considerations: Translational principles of neural tissue engineering (NTE)
  • 3: Summary and future outlook
  • References
  • 23: Multifunctional liposome-quantum dot hybrid nanocarriers for drug targeting to brain tumors
  • Abstract
  • 1: Introduction
  • 2: Liposomes in brain tumors
  • 3: Quantum dots (QDs)
  • 4: Liposome and QD hybridization
  • 5: Targeting of brain tumors
  • 6: Future perspectives
  • References
  • 24: Drug-loaded nanoclusters for brain targeting
  • Abstract
  • Conflict of interest
  • 1: Introduction
  • 2: Blood-brain barrier
  • 3: Applications of nanoclusters in brain-related disorders
  • 4: Conclusions
  • References
  • 25: Nanomedicines for tropical diseases affecting the central nervous system
  • Abstract
  • 1: Introduction
  • 2: Overview of cerebral tropical diseases
  • 3: Mechanism of therapeutic agents targeting the CNS
  • 4: Conventional drug delivery strategies for CNS delivery
  • 5: Nanocarrier strategies for CNS drug delivery
  • 6: Conclusions
  • References
  • 26: Brain specific delivery of phytoconstituents through nanodrug wagons approach
  • Abstract
  • 1: Introduction
  • 2: Curcumin
  • 3: Resveratrol
  • 4: Camptothecin
  • 5: Paclitaxel
  • 6: Gallic acid
  • 7: Ginsenoside Rg3
  • 8: Asiatic acid
  • 9: Bacopaside II
  • 10: Trigonelline
  • 11: Vincristine
  • 12: Capsaicin
  • 13: Berberine
  • 14: Genistein
  • 15: Ethical standpoints
  • 16: Future perspectives
  • 17: Conclusion
  • References
  • 27: Multifunctional nanocarrier systems targeting brain tumors: A review
  • Abstract
  • 1: Introduction
  • 2: Multifunctional nanocarriers for tumor-targeted delivery
  • 3: Multifunctional nanocarrier targeting brain tumors
  • 4: Passive targeting with nanoparticles in brain tumors
  • 5: Active targeting with nanoparticles in brain tumors
  • 6: Parameters of multifunctional nanocarriers in brain tumors
  • 7: Conclusion
  • References
  • Part H: Future directions and toxic concerns
  • 28: Expert opinion on current challenges and future directions of nanocarriers for brain targeted drug delivery
  • Abstract
  • Conflict of interest
  • Acknowledgments
  • 1: Introduction
  • 2: Challenges encountered by NCs in brain-targeted drug delivery
  • 3: Future prospects
  • 4: Conclusion
  • References
  • 29: Biological nanodrugs for brain targeting
  • Abstract
  • 1: Nanomedicine
  • 2: Nanodrugs
  • 3: Global disease burden and the value of the central nervous system disease market
  • 4: Conclusion
  • References
  • Index

Product details

  • No. of pages: 856
  • Language: English
  • Copyright: © Elsevier 2022
  • Published: June 21, 2022
  • Imprint: Elsevier
  • Paperback ISBN: 9780323907736
  • eBook ISBN: 9780323914710

About the Editors

Lalit Kumar

Lalit Kumar, is Assistant Professor in the Department of Pharmaceutics, at Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lung.

Affiliations and Expertise

Assistant Professor, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India

Yashwant Pathak

Yashwant Pathak, is Professor and Associate Dean for the Faculty Affairs at the College of Pharmacy, at the University of South Florida. Tampa, USA. His area of research is in health care education, nanotechnology, drug delivery systems and nutraceuticals.

Affiliations and Expertise

Professor and Associate Dean, Faculty Affairs, College of Pharmacy, University of South Florida, Tampa, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Nanocarriers for Drug-Targeting Brain Tumors"